博济医药 (300404.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	949.9M	868.6M	742.0M	555.8M	423.7M
Cost of Revenue	694.2M	633.0M	516.6M	370.5M	263.0M
Gross Profit	255.8M	235.6M	225.4M	185.3M	160.7M
Operating Expenses
R&D Expense	60.1M	57.5M	62.6M	55.0M	43.7M
SG&A Expense	—	—	—	—	—
General & Admin Expense	66.0M	66.7M	70.6M	67.0M	57.6M
Selling & Marketing Expense	57.0M	56.9M	53.8M	42.0M	31.1M
Other Expenses	—	—	—	—	—
Total Operating Expenses	191.9M	189.6M	195.0M	168.0M	135.5M
Cost and Expenses	886.1M	822.6M	711.6M	538.6M	398.5M
Operating Income (EBIT)	47.1M	31.3M	18.6M	17.6M	19.5M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	45.9M	30.1M	18.4M	17.6M	24.6M
Income Tax Expense	1.6M	(2.9M)	(12.2M)	(9.6M)	(4.7M)
Bottom Line
Net Income	43.1M	30.5M	28.8M	24.3M	27.7M
Earnings from Cont. Ops	44.3M	32.9M	30.7M	27.2M	29.3M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	43.1M	30.5M	28.8M	24.3M	27.7M
Per Share
Basic EPS	CN¥0.11	CN¥0.08	CN¥0.08	CN¥0.07	CN¥0.08
Diluted EPS	CN¥0.11	CN¥0.08	CN¥0.08	CN¥0.07	CN¥0.08
Revenue Per Share	CN¥2.48	CN¥2.26	CN¥1.94	CN¥1.50	CN¥1.15
Shares
Basic Shares Outstanding	382.8M	384.1M	382.2M	370.5M	367.5M
Diluted Shares Outstanding	382.8M	384.1M	382.2M	370.5M	367.5M
Profitability Metrics
EBITDA	—	64.7M	46.8M	42.3M	41.3M
D&A	—	33.4M	28.2M	24.7M	21.8M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026